Androgen deficiency in aging men: Role of testosterone replacement therapy

Journal of Laboratory and Clinical Medicine

Volumn 135, Issue 5, 2000, Pages 370-378

  Morley, John E ^a,b   Perry III, Horace M ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033807039     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1067/mlc.2000.106455     Document Type: Conference Paper

References (129)

1. Effects in man of subcutaneous injections of freshly prepared liquid guinea pig and dog testes
2. The physiological and therapeutic of animal testicular extract based on several experiments in man
3. The pentacle of rejuvenescence
4. Uber krystallin isches mannliches hormon ous hoden (testosterone), wirk-samer als aus ham oder aus cholesterin beneitetis androsteron
5. Testis
6. The male climacteric: Report of two hundred and seventy-three cases
7. The male climacteric: Its symptomatology, diagnosis and treatment
8. Testosterone implantation: A clinical study of 240 implantation in ageing males
9. Androgens in the aging male
10. Clinical review 34: Androgen treatment of hypogonadal men
11. Age related changes in free plasma testosterone, dihydrotestosterone and oestradiol
12. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts male aging study
13. Further studies on Leydig cell function in old age
14. Effects of androgens, estrogens and high calcium intakes on bone formation and resorption in osteoporosis
15. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men
16. Reproductive effects of nontesticular illness
17. Testicular dysfunction in systemic disease
18. Gonadal dysfunction in systemic disorders
19. Age, disease, and changing sex hormone levels in middle-aged men: Results of the Massachusetts Male Aging Study
20. Sertoli cell function declines earlier than Leydig cell function in aging Japanese men
21. Impotence and aging: Clinical and hormonal factors
22. Secondary hypogonadism in older men: Its relation to impotence
23. Decreased bioavailable testosterone in aging normal and impotent men
24. Testosterone deficiency myopathy
25. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men
26. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men
27. Testosterone and frailty
28. Impotence: The internist's approach to diagnosis and treatment
29. Further studies on Leydig cell function in old age
30. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin
31. The effect of human chorionic gonadotropin on plasma steroid levels in young and old men
32. Impaired in vitro testicular endocrine function in elderly men
33. Differential responses of biologically active luteinizing hormone secretion in older versus young men to interruption of androgen negative feedback
34. The gonadotropin-suppressive activity of androgen is increased in elderly men
35. Attenuation of luteinizing hormone secretory burst amplitude as a proximate basis for the hypoandrogenism of healthy aging in men
36. Endocrine effects of naloxone-induced opiate receptor blockade
37. Effects of opioid blockade with nalmefene in older impotent men
38. Role of the hypothalamic opioidergic system in the control of gonadotropin secretion in elderly men
39. The effects of aging in normal men on bioavailable testosterone and luteinizing hormone secretion: Response to clomiphene citrate
40. Influence of age and sex on serum concentrations of total dimercic activin A
41. Effects of androgen on sexual behavior in hypogonadal men
42. The relationship between pituitary-gonadal function and sexual behavior in healthy aging men
43. Testosterone supplementation for hypogonadal impotence: Assessment of biochemical measures and therapeutic outcomes
44. Clinical and hormonal effects of testosterone undecanoate (TU) in male sexual impotence
45. Effects of androgen treatment in impotent men with normal and low levels of free testosterone
46. Androgen replacement and oral testosterone undecanoate in hypogonadal men: A double blind controlled study
47. Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients
48. Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis
49. Testosterone therapy in impotent patients with normal testosterone
50. Androgens modulate nitric oxide synthase messenger ribonucleic acid expression in neurons of the major pelvic ganglion in the rat
51. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
52. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men: A clinical research center study
53. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis
54. Effect of training on muscle strength and motor function in the elderly
55. Predictors of skeletal muscle mass in elderly men and women
56. Testosterone deficiency myopathy
57. Effects of testosterone replacement therapy in old hypogonadal males: A preliminary study
58. Testosterone replacement in older hypogonadal men: A 12 month randomized controlled trial
59. Leptin and the regulation of body weight in mammals
60. Effect of leptin deficiency on metabolic rate in ob/ob mice
61. A leptin missense mutation associated with hypogonadism and morbid obesity
62. Congenital leptin deficiency is associated with severe early-onset obesity in humans
63. Leptin, adipose tissue and aging: Is there a role for testosterone?
64. Leptin and neuropeptide Y modulate nitric oxide synthase: Further evidence for a role of nitric oxide in feeding peptides
65. Body composition and age in African-American and Caucasian women: Relationship to plasma leptin levels
66. Effects of gender, body composition, and menopause on plasma concentrations of leptin
67. Serum leptin in elderly people: Associations with sex hormones, insulin, and adipose tissue volumes
68. Agerelated changes in sex hormones affect the sex difference in serum leptin independently of changes in body fat
69. Strong association between serum levels of leptin and testosterone in men
70. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men
71. In vivo and in vitro ob gene expression and leptin secretion in rat adipocytes: Evidence for a regional specific regulation by sex steroid hormones
72. Androgen treatment of middle-aged, obese men: Effects on metabolism, muscle and adipose tissues
73. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men
74. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels
75. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men
76. High-affinity androgen binding and androgenic regulation of alpha 1(I)-procollagen and transforming growth factor-beta steady state messenger ribonucleic acid levels in human osteoblast-like osteosarcoma cells
77. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
78. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency
79. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality
80. Risk factors for increased bone loss in an elderly population: The Rotterdam Study
81. Epidemiology of hip fractures
82. Determinants of reduced survival following hip fractures in men
83. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men?
84. Observations on nursing home residents with a history of hip fracture
85. Testosterone deficiency as a risk factor for hip fractures in men: A case-control study
86. Testosterone therapy in glucocorticoid-treated men
87. Gender differences in cognitive function with age: The Rancho Bernardo study
88. Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it
89. Animal models of Alzheimer disease
90. Learning and memory in the SAMP8 mouse
91. Age-related decrease of plasma testosterone in SAMP8 mice: Replacement improves age-related impairment of learning and memory
92. Is there a role for estrogen replacement therapy in the prevention and treatment of dementia?
93. The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature
94. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: Progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone
95. Testosterone administration improves spatial and verbal memory in normal men
96. Testosterone influences spatial cognition in older men
97. Add-back estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri
98. Testosterone treatment restores reduced vasopressin-binding sites in the kidney of the ageing rat
99. Effects of sex steroid hormones on arginine vasopressin in intact and castrated male and female rats
100. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels
101. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate
102. A ten-year safety study of the oral androgen testosterone undecanoate
103. Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system
104. Testosterone and the older man
105. Androgen deficiency in aging males
106. Effects of testosterone supplementation in the aging male
107. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men
108. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone
109. Longitudinal evaluation of serum androgen levels in men with or without prostate cancer
110. Low serum testosterone and a younger age predict a poor outcome in metastatic prostate cancer
111. Testosterone and risk factors for cardiovascular disease in men
112. Visceral adipositiy, androgens, and plasma lipids in obese men
113. Lower endogenous androgens predict central adiposity in men
114. The association of hypotestosteronemia with coronary artery disease in men
115. Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study
116. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men
117. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients
118. Effect of testosterone cypionate on postexercise ST segment depression
119. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo
120. Testosterone relaxes rabbit coronary arteries and aorta
121. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease
122. Acute anti-ischemic effect of testosterone in men with coronary artery disease
123. Results of testosterone enanthate therapy in older men
124. Effect of testosterone treatment on bone mineral density in men over 65 years of age